Page 37 - Regarding Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jaguar Health, Inc. Reports 2021 First Quarter Financial Results ACCESSWIRE 17 May 2021, 22:05 GMT+10 First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today reported consolidated first quarter 2021 financial results. 2021 First Quarter Company Financia...

Halozyme Reports First Quarter 2021 Results - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 - - Reiterate 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue - - Reiterate 2021 GAAP Operating Income Guidance of $215 million to $235 million, Representing 49%-63% Growth over 2020 GAAP Operating Income - News provided by Share this article Share this article SAN DIEGO, May 10, 2021 /PRNews...

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced... | May 5, 2021

Search jobs Glaukos Corporation Announces First Quarter 2021 Financial Results SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: Net sales growth of 23% to $68.0 million in Q1 2021, compared to $55.3 million in Q1 2020. Glaucoma net sales of $53.7 million and Corneal Health net sales of $14...

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma New collaboration with Cyto...